Drug Trial Radar · NCT07733765
A Study in Young People and Adults to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair Loss, Known by the Medical Term as Moderate Alopecia Areata
Last checked: Nov 20, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
336
Planned (sponsor's estimate)
Start
Jul 30, 2026
Primary completion
Apr 26, 2028
Study completion Apr 26, 2028
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Jul 29, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this clinical study is to learn about the safety and effects of the study medicine (called ritlecitinib) for the potential treatment of moderate alopecia areata (AA). This study is seeking participants who are * 12 years or older (if permitted by the local IRB/EC and local regulatory health authority) * have AA with patchy hair loss. The current episode of hair loss has lasted for 6 months or longer but 10 years or less * do not have any other diseases or conditions affecting hair loss. Participants will have a 2 in 3 chance of receiving ritlecitinib 50 mg and a 1 in 3 chance of receiving placebo. The placebo looks like the study medicine but does not contain any active ingredients. Participants will not know what you have been assigned to receive. They will take ritlecitinib or placebo once daily by mouth at home for 24 weeks (6 months). After 24 weeks, the assigned treatment may stay the same or be changed to ritlecitinib 50 mg or 100 mg. This change will depend on how participants' alopecia areata responds to the treatment. Participants will receive the newly assigned treatment for another 23 weeks. About 4 weeks after the last dose, there will be a follow-up visit. At this visit, the team will check on your health. Participants will take part in this study for about 57 weeks. During this time, they will have study visits at the study clinic. Some study checks will be done by phone. We will compare the experiences of people receiving ritlecitinib to those of people who do not. This will help us determine if ritlecitinib is safe and effective.
Conditions
- Alopecia Areata
Interventions
Ritlecitinib 100 mgDrug
100 mg capsule taken orally once daily
Ritlecitinib 50 mgDrug
50 mg capsule taken orally once daily
PlaceboOther
Capsule matching either 50mg or 100 mg ritlecitinib capsule taken orally once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Difference in the proportion of Severity of Alopecia Tool (SALT) 0 responders at Week 24 between ritlecitinib 50 mg QD versus placeboTime frame: Week 24
Locations
38 sites in 5 countries. Site status is shown where the registry gives one.
California Dermatology & Clinical Research Institute
Encinitas, California · Recruiting
Skin Research of South Florida
Miami, Florida · Recruiting
Endeavor Health
Skokie, Illinois · Not yet recruiting
Dawes Fretzin Clinical Research Group, LLC
Indianapolis, Indiana · Recruiting
University of Iowa
Iowa City, Iowa · Not yet recruiting
Cutaneous Translational Research Program, Johns Hopkins University School of Medicine
Baltimore, Maryland · Not yet recruiting
Johns Hopkins Hospital Investigational Drug Services (IDS) Pharmacy
Baltimore, Maryland · Not yet recruiting
Massachusetts General Hospital - Clinical Unit for Research Trials in Skin (CURTIS)
Boston, Massachusetts · Recruiting
Revival Research Institute, LLC
Troy, Michigan · Recruiting
Clinical and Translational Research Center (CTRC)
Chapel Hill, North Carolina · Recruiting
UNC Dermatology and Skin Cancer Center
Chapel Hill, North Carolina · Recruiting
Audiology & Hearing Services
Charlotte, North Carolina · Recruiting
Carolinas Imaging Service
Charlotte, North Carolina · Recruiting
Darst Dermatology
Charlotte, North Carolina · Recruiting
Bexley Dermatology Research
Bexley, Ohio · Recruiting
NW Dermatology Institute
Portland, Oregon · Recruiting
Dermatology Associates of Plymouth Meeting
Plymouth Meeting, Pennsylvania · Recruiting
Center for Clinical Studies, LTD. LLP
Houston, Texas · Recruiting
Texas Dermatology and Laser Specialists
San Antonio, Texas · Recruiting
Dermatology Specialists of Spokane
Spokane, Washington · Not yet recruiting
Principle Research Solutions
Spokane, Washington · Not yet recruiting
Wiseman Dermatology Research Inc.
Winnipeg, Manitoba, Canada · Recruiting
The Centre for Clinical Trials
Oakville, Ontario, Canada · Recruiting
Research Toronto
Toronto, Ontario, Canada · Recruiting
Centre de Recherche Saint-Louis (Montréal)
Montreal, Quebec, Canada · Recruiting
Centre de Recherche Saint-Louis (Québec)
Québec, Quebec, Canada · Recruiting
Beijing Friendship Hospital
Beijing, Beijing Municipality, China · Not yet recruiting
Huashan Hospital, Fudan University
Shanghai, Shanghai Municipality, China · Recruiting
Niigata University Medical & Dental Hospital
Niigata, Japan · Recruiting
Osaka Metropolitan University Hospital
Osaka, Japan · Recruiting
Hospital of the University of Occupational and Environmental Health, Japan
Kitakyushu-shi, Fukuoka, Japan · Recruiting
Hamamatsu University Hospital
Hamamatsu, Shizuoka, Japan · Recruiting
Juntendo Tokyo Koto Geriatric Medical Center
Koto-ku, Tokyo, Japan · Recruiting
Kyorin University Hospital
Mitaka, Tokyo, Japan · Recruiting
Tokyo Medical University Hospital
Shinjuku-ku, Tokyo, Japan · Recruiting
Seoul National University Hospital
Seoul, South Korea · Recruiting
Jeonbuk National University Hospital
Jeonju, Jeonrabugdo,, South Korea · Not yet recruiting
Kyung Hee University Hospital at Gangdong
Seoul, Seoul-teukbyeolsi [seoul], South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.